Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

GM Pharma International Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (365)
Cancellation by sponsor (13)

Date

2026 (15)
2025 (8)
2024 (113)
2023 (10)
2022 (2)
2021 (6)
2020 (56)
2019 (6)
2018 (21)
2017 (19)
2016 (16)
2015 (19)
2014 (18)
2013 (16)
2012 (18)
2011 (13)
2010 (4)
2009 (6)
2007 (7)
2006 (4)
2005 (1)

Search

Sponsor content

378 result(s) found, displaying 1 to 10

FEBUXOSTAT-WGR febuxostat 80 mg tablet blister pack (525605)

13 July 2026

ARTG

Australian Register of Therapeutic Goods (ARTG) information for FEBUXOSTAT-WGR febuxostat 80 mg tablet blister pack.
PARACODEX 450/30/5 paracetamol 450 mg/codeine phosphate hemihydrate 30 mg/doxylamine succinate 5 mg tablet blister pack (520859)

21 May 2026

ARTG

Australian Register of Therapeutic Goods (ARTG) information for PARACODEX 450/30/5 paracetamol 450 mg/codeine phosphate hemihydrate 30 mg/doxylamine succinate 5 mg tablet blister pack.
RASAGILINE-WGR rasagiline (as mesilate) 1 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

29 June 2026

Cancellation by sponsor

Requested by GM Pharma International Pty Ltd
ARIPIPRAZOLE-WGR 20 mg aripiprazole tablets blister pack Cancelled under Section 30(1)(c) of the Act

29 June 2026

Cancellation by sponsor

Requested by GM Pharma International Pty Ltd
ARIPIPRAZOLE-WGR 30 mg aripiprazole tablets blister pack Cancelled under Section 30(1)(c) of the Act

29 June 2026

Cancellation by sponsor

Requested by GM Pharma International Pty Ltd
ARIPIPRAZOLE-WGR 5 mg aripiprazole tablets blister pack Cancelled under Section 30(1)(c) of the Act

29 June 2026

Cancellation by sponsor

Requested by GM Pharma International Pty Ltd
OLANZAPINE ODT-WGR olanzapine 15 mg orally disintegrating tablet blister pack Cancelled under Section 30(1)(c) of the Act

29 June 2026

Cancellation by sponsor

Requested by GM Pharma International Pty Ltd
OLANZAPINE ODT-WGR olanzapine 5 mg orally disintegrating tablet blister pack Cancelled under Section 30(1)(c) of the Act

29 June 2026

Cancellation by sponsor

Requested by GM Pharma International Pty Ltd
OLANZAPINE ODT-WGR olanzapine 20 mg orally disintegrating tablet blister pack Cancelled under Section 30(1)(c) of the Act

29 June 2026

Cancellation by sponsor

Requested by GM Pharma International Pty Ltd
OLANZAPINE ODT-WGR olanzapine 10 mg orally disintegrating tablet blister pack Cancelled under Section 30(1)(c) of the Act

29 June 2026

Cancellation by sponsor

Requested by GM Pharma International Pty Ltd

Pages

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.